Ⅲ期黑色素瘤围手术期治疗的现状与展望

徐宇; 陈勇; 杨吉龙; 朱冠男

doi:10.19401/j.cnki.1007-3639.2022.12.001

您当前的位置：

首页 >

文章列表页 >

Ⅲ期黑色素瘤围手术期治疗的现状与展望

专家述评 | 更新时间：2025-12-31

- Ⅲ期黑色素瘤围手术期治疗的现状与展望
- Current status and prospect of perioperative treatment of stage Ⅲ melanoma
- 中国癌症杂志 2022年32卷第12期页码：1133-1146
- 作者机构：
  
  1. 复旦大学附属肿瘤医院骨软组织外科，复旦大学上海医学院肿瘤学系，上海 200032
  2. 天津医科大学肿瘤医院骨与软组织肿瘤科，国家恶性肿瘤临床医学研究中心，天津 300060
  3. 天津市恶性肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津市肿瘤分子流行病重点实验室，天津 300060
  4. 空军军医大学（第四军医大学）西京皮肤医院，陕西西安 710032
- 作者简介：
  
  [ "徐宇（ORCID：0000-0002-0894-5311），副主任医师。" ]
  [ "朱冠男，医学博士，副主任医师，硕士生导师。现任空军军医大学（第四军医大学）西京医院皮肤科性病真菌中心主任，中国抗癌协会黑色素瘤专业委员会常务委员兼秘书长，中国指南科学性、透明性和适用性评级（STAR）皮肤科专业委员会副主任委员，陕西省医师协会皮肤科医师分会青年委员会副主任委员，中国医师协会皮肤科医师分会自身免疫病学组委员，欧洲化脓性汗腺炎基金会（EHSF）成员。主持国家自然科学基金2项，军队人才项目基金1项；以第一作者及通信作者在SCI收录期刊上发表论文20余篇，其中多篇发表在Journal of Investigative Dermatology、Autophagy、Journal of Allergy and Clinical Immunology、Cancer Letters等业内顶尖期刊。" ]
- 基金信息：
  
  国家自然科学基金(82172607);国家自然科学基金面上项目(82272857);国家自然科学基金(81802636);临港实验室基金(LG-QS-202205-11);上海市科学技术委员会科研计划(19411951700)
- DOI：10.19401/j.cnki.1007-3639.2022.12.001
  中图分类号： R739.5
- 收稿：2022-11-22，
  
  修回：2022-12-27，
  
  纸质出版：2022-12-30
- 稿件说明：
移动端阅览
徐宇, 陈勇, 杨吉龙, 等. Ⅲ期黑色素瘤围手术期治疗的现状与展望[J]. 中国癌症杂志, 2022,32(12):1133-1146.

Yu XU, Yong CHEN, Jilong YANG, et al. Current status and prospect of perioperative treatment of stage Ⅲ melanoma[J]. China Oncology, 2022, 32(12): 1133-1146.
徐宇, 陈勇, 杨吉龙, 等. Ⅲ期黑色素瘤围手术期治疗的现状与展望[J]. 中国癌症杂志, 2022,32(12):1133-1146. DOI： 10.19401/j.cnki.1007-3639.2022.12.001.

Yu XU, Yong CHEN, Jilong YANG, et al. Current status and prospect of perioperative treatment of stage Ⅲ melanoma[J]. China Oncology, 2022, 32(12): 1133-1146. DOI： 10.19401/j.cnki.1007-3639.2022.12.001.

摘要

黑色素瘤是一种恶性程度极高的肿瘤，早期黑色素瘤经手术切除多可治愈，但对于高危型病例（ⅡB~Ⅳ期），辅助治疗是延长患者生命、改善预后的重要手段。近年来随着系统治疗药物的蓬勃发展，对于Ⅲ期可切除病例的围手术期治疗理念不断发生变化。本文着眼于外科手术规范及对预后的影响、术后辅助治疗选择、新辅助治疗的进展等热点问题进行梳理，并结合来源于中国患者的治疗数据进行分析讨论，希望为中国Ⅲ期黑色素瘤的围手术期治疗选择提供新的思路。

Abstract

Melanoma is one of the most dangerous tumors due to its high-grade malignancy. Though patients in early stage can be completely cured by surgery

for high-risk cases (stage ⅡB-Ⅳ)

adjuvant therapy is of great importance to prolong the survival and improve the prognosis. In recent years

thanks to the booming development of systemic regimen

the perioperative managements for stage Ⅲ cases have been continuously evolving. In the current paper

we focused on the role of lymph node biopsy and surgical resection

postoperative adjuvant therapy options

as well as the cutting-edge neoadjuvant therapy development

aiming to provide new perioperative strategies for stage Ⅲ melanoma patients.

关键词

Keywords

references

中国抗癌协会肉瘤专业委员会软组织肉瘤及恶性黑色素瘤学组 . 皮肤和肢端恶性黑色素瘤的外科治疗规范中国专家共识1.0 [J ] . 中华肿瘤杂志 , 2020 , 42 ( 2 ): 81 - 93 .

Group of Soft Tissue Sarcoma and Malignant Melanoma, Sarcoma Professional Committee of Chinese Anti-Cancer Association . Chinese expert consensus on the surgical treatment of cutaneous/acral melanoma V1.0 [J ] . Chin J Oncol , 2020 , 42 ( 2 ): 81 - 93 .

MORTON D L , THOMPSON J F , COCHRAN A J , et al . Final trial report of sentinel-node biopsy versus nodal observation in melanoma [J ] . N Engl J Med , 2014 , 370 ( 7 ): 599 - 609 . DOI: 10.1056/NEJMoa1310460 http://doi.org/10.1056/NEJMoa1310460 http://www.nejm.org/doi/10.1056/NEJMoa1310460 http://www.nejm.org/doi/10.1056/NEJMoa1310460

FARIES M B , THOMPSON J F , COCHRAN A J , et al . Completion dissection or observation for sentinel-node metastasis in melanoma [J ] . N Engl J Med , 2017 , 376 ( 23 ): 2211 - 2222 . DOI: 10.1056/NEJMoa1613210 http://doi.org/10.1056/NEJMoa1613210 http://www.nejm.org/doi/10.1056/NEJMoa1613210 http://www.nejm.org/doi/10.1056/NEJMoa1613210

LEITER U , STADLER R , MAUCH C , et al . Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node [J ] . J Clin Oncol , 2019 , 37 ( 32 ): 3000 - 3008 . DOI: 10.1200/JCO.18.02306 http://doi.org/10.1200/JCO.18.02306

WEI X T , WU D , LI H , et al . The clinicopathological and survival profiles comparison across primary sites in acral melanoma [J ] . Ann Surg Oncol , 2020 , 27 ( 9 ): 3478 - 3485 . DOI: 10.1245/s10434-020-08418-5 http://doi.org/10.1245/s10434-020-08418-5

HUANG K , FAN J , MISRA S . Acral lentiginous melanoma: Incidence and survival in the United States, 2006-2015, an analysis of the SEER registry [J ] . J Surg Res , 2020 , 251 : 329 - 339 . DOI: S0022-4804(20)30097-4 http://doi.org/S0022-4804(20)30097-4

MANDALÀ M , RUTKOWSKI P , GALLI F , et al . Acral lentiginous melanoma histotype predicts outcome in clinical stage Ⅰ-Ⅱ melanoma patients: an international multicenter study [J ] . ESMO Open , 2022 , 7 ( 3 ): 100469.

徐宇 , 朱蕙燕 , 陈勇 , 等 . 前哨淋巴结活检在中国皮肤和肢端恶性黑色素瘤患者诊治中的临床意义 [J ] . 中国癌症杂志 , 2018 , 28 ( 11 ): 819 - 826 .

XU Y , ZHU H Y , CHEN Y , et al . The clinical significance of sentinel lymph node biopsy in the Chinese patients with cutaneous and acral melanoma [J ] . China Oncol , 2018 , 28 ( 11 ): 819 - 826 .

SUN W , XU Y , YANG J L , et al . The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-a multicenter retrospective study [J ] . Cancer Commun (Lond) , 2020 , 40 ( 11 ): 586 - 597 .

BHAVE P , PALLAN L , LONG G V , et al . Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis [J ] . Br J Cancer , 2021 , 124 ( 3 ): 574 - 580 . DOI: 10.1038/s41416-020-01121-y http://doi.org/10.1038/s41416-020-01121-y https://doi.org/10.1038/s41416-020-01121-y https://doi.org/10.1038/s41416-020-01121-y

OWEN C N , SHOUSHTARI A N , CHAUHAN D , et al . Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy [J ] . Ann Oncol , 2020 , 31 ( 8 ): 1075 - 1082 . DOI: S0923-7534(20)39788-X http://doi.org/S0923-7534(20)39788-X

WEBER J S , SCHADENDORF D , DEL VECCHIO M , et al . Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage ⅢB-D or stage Ⅳ melanoma (CheckMate 915) [J ] . J Clin Oncol , 2022 : JCO2200533.

LARKIN J , WEBER J , DEL VECCHIO M , et al . Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage Ⅲ melanoma per AJCC-8 staging criteria [J ] . Eur J Cancer , 2022 , 173 : 285 - 296 . DOI: 10.1016/j.ejca.2022.06.041 http://doi.org/10.1016/j.ejca.2022.06.041 https://linkinghub.elsevier.com/retrieve/pii/S0959804922003926 https://linkinghub.elsevier.com/retrieve/pii/S0959804922003926

COCHRAN A J , WEN D R , HUANG R R , et al . Sentinel lymph node melanoma metastases: assessment of tumor burden for clinical prediction of outcome in the first multicenter selective lymphadenectomy trial (MSLT-I) [J ] . Eur J Surg Oncol , 2022 , 48 ( 6 ): 1280 - 1287 . DOI: 10.1016/j.ejso.2022.01.021 http://doi.org/10.1016/j.ejso.2022.01.021

MONCRIEFF M D , LO S N , SCOLYER R A , et al . Clinical outcomes and risk stratification of early-stage melanoma micrometastases from an international multicenter study: implications for the management of American Joint Committee on Cancer ⅢA disease [J ] . J Clin Oncol , 2022 , 40 ( 34 ): 3940 - 3951 . DOI: 10.1200/JCO.21.02488 http://doi.org/10.1200/JCO.21.02488 https://ascopubs.org/doi/10.1200/JCO.21.02488 https://ascopubs.org/doi/10.1200/JCO.21.02488

GERSHENWALD J E , SCOLYER R A , HESS K R , et al . Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual [J ] . CA Cancer J Clin , 2017 , 67 ( 6 ): 472 - 492 . DOI: 10.3322/caac.21409 http://doi.org/10.3322/caac.21409 http://doi.wiley.com/10.3322/caac.21409 http://doi.wiley.com/10.3322/caac.21409

樊代明 , 主编. 中国肿瘤整合诊治指南(CACA)-2022-黑色素瘤 [M ] . 天津 : 天津科学技术出版社 , 2022 .

FAN D M , editor-in-chief. Chinese guidelines for integrated cancer diagnosis and treatment (CACA)-2022-melanoma [M ] . Tianjin Science and Technology Press , 2022 .

中国临床肿瘤学会指南工作委员会组织 . 中国临床肿瘤学会(CSCO)黑色素瘤诊疗指南-2021 [M ] . 北京 : 人民卫生出版社 , 2021 .

Working Committee on Guidelines of Chinese Society of Clinical Oncology . Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of melanoma-2021 [M ] . People 's Medical Publishing House , 2021 .

EGGERMONT A M , CHIARION-SILENI V , GROB J J , et al . Prolonged survival in stage Ⅲ melanoma with ipilimumab adjuvant therapy [J ] . N Engl J Med , 2016 , 375 ( 19 ): 1845 - 1855 . DOI: 10.1056/NEJMoa1611299 http://doi.org/10.1056/NEJMoa1611299 http://www.nejm.org/doi/10.1056/NEJMoa1611299 http://www.nejm.org/doi/10.1056/NEJMoa1611299

ASCIERTO P A , et al . Adjuvant nivolumab versus ipilimumab in resected stage ⅢB-C and stage Ⅳ melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 11 ): 1465 - 1477 . DOI: 10.1016/S1470-2045(20)30494-0 http://doi.org/10.1016/S1470-2045(20)30494-0 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304940 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304940

EGGERMONT A M M , BLANK C U , MANDALÀ M , et al . Adjuvant pembrolizumab versus placebo in resected stage Ⅲ melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial [J ] . Lancet Oncol , 2021 , 22 ( 5 ): 643 - 654 . DOI: 10.1016/S1470-2045(21)00065-6 http://doi.org/10.1016/S1470-2045(21)00065-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204521000656 https://linkinghub.elsevier.com/retrieve/pii/S1470204521000656

DUMMER R , BRASE J C , GARRETT J , et al . Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF V600 -mutant, stage Ⅲ melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 3 ): 358 - 372 . DOI: 10.1016/S1470-2045(20)30062-0 http://doi.org/10.1016/S1470-2045(20)30062-0 https://linkinghub.elsevier.com/retrieve/pii/S1470204520300620 https://linkinghub.elsevier.com/retrieve/pii/S1470204520300620

DUMMER R , HAUSCHILD A , SANTINAMI M , et al . Five-year analysis of adjuvant dabrafenib plus trametinib in stage Ⅲ melanoma [J ] . N Engl J Med , 2020 , 383 ( 12 ): 1139 - 1148 . DOI: 10.1056/NEJMoa2005493 http://doi.org/10.1056/NEJMoa2005493 http://www.nejm.org/doi/10.1056/NEJMoa2005493 http://www.nejm.org/doi/10.1056/NEJMoa2005493

KIRKWOOD J M , MANOLA J , IBRAHIM J , et al . A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma [J ] . Clin Cancer Res , 2004 , 10 ( 5 ): 1670 - 1677 . DOI: 10.1158/1078-0432.ccr-1103-3 http://doi.org/10.1158/1078-0432.ccr-1103-3

IVES N J , SUCIU S , EGGERMONT A M M , et al . Adjuvant interferon-α for the treatment of high-risk melanoma: an individual patient data meta-analysis [J ] . Eur J Cancer , 2017 , 82 : 171 - 183 . DOI: S0959-8049(17)31032-8 http://doi.org/S0959-8049(17)31032-8

PEHAMBERGER H , SOYER H P , STEINER A , et al . Adjuvant interferon alfa-2a treatment in resected primary stage Ⅱ cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group [J ] . J Clin Oncol , 1998 , 16 ( 4 ): 1425 - 1429 . DOI: 10.1200/JCO.1998.16.4.1425 http://doi.org/10.1200/JCO.1998.16.4.1425 https://ascopubs.org/doi/10.1200/JCO.1998.16.4.1425 https://ascopubs.org/doi/10.1200/JCO.1998.16.4.1425

KIRKWOOD J M , IBRAHIM J G , SONDAK V K , et al . High- and low-dose interferon Alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 [J ] . J Clin Oncol , 2000 , 18 ( 12 ): 2444 - 2458 . DOI: 10.1200/JCO.2000.18.12.2444 http://doi.org/10.1200/JCO.2000.18.12.2444

LI T , JIA D D , TENG L S . Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage Ⅲ melanoma: a retrospective cohort study [J ] . Invest New Drugs , 2020 , 38 ( 5 ): 1334 - 1341 . DOI: 10.1007/s10637-020-00913-6 http://doi.org/10.1007/s10637-020-00913-6 https://doi.org/10.1007/s10637-020-00913-6 https://doi.org/10.1007/s10637-020-00913-6

JIA D D , NIU Y L , ZHU H L , et al . Prior therapy with pegylated-interferon Alfa-2b improves the efficacy of adjuvant pembrolizumab in resectable advanced melanoma [J ] . Front Oncol , 2021 , 11 : 675873.

LIAN B , SI L , CHI Z H , et al . Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase Ⅱ randomized trial [J ] . Ann Oncol , 2022 , 33 ( 10 ): 1061 - 1070 . DOI: 10.1016/j.annonc.2022.07.002 http://doi.org/10.1016/j.annonc.2022.07.002 https://linkinghub.elsevier.com/retrieve/pii/S092375342201849X https://linkinghub.elsevier.com/retrieve/pii/S092375342201849X

TRIMBLE E L , UNGERLEIDER R S , ABRAMS J A , et al . Neoadjuvant therapy in cancer treatment [J ] . Cancer , 1993 , 72 (11 Suppl): 3515 - 3524 . DOI: 10.1002/1097-0142(19931201)72:11+<3515::aid-cncr2820721619>3.0.co;2-a http://doi.org/10.1002/1097-0142(19931201)72:11+<3515::aid-cncr2820721619>3.0.co;2-a

BUZAID A C , COLOME M , BEDIKIAN A , et al . Phase Ⅱ study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases [J ] . Melanoma Res , 1998 , 8 ( 6 ): 549 - 556 . DOI: 10.1097/00008390-199812000-00010 http://doi.org/10.1097/00008390-199812000-00010 http://journals.lww.com/00008390-199812000-00010 http://journals.lww.com/00008390-199812000-00010

LEWIS K D , ROBINSON W A , MCCARTER M , et al . Phase Ⅱ multicenter study of neoadjuvant biochemotherapy for patients with stage Ⅲ malignant melanoma [J ] . J Clin Oncol , 2006 , 24 ( 19 ): 3157 - 3163 . DOI: 10.1200/JCO.2005.04.5344 http://doi.org/10.1200/JCO.2005.04.5344 https://ascopubs.org/doi/10.1200/JCO.2005.04.5344 https://ascopubs.org/doi/10.1200/JCO.2005.04.5344

MOSCHOS S J , EDINGTON H D , LAND S R , et al . Neoadjuvant treatment of regional stage ⅢB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses [J ] . J Clin Oncol , 2006 , 24 ( 19 ): 3164 - 3171 . DOI: 10.1200/JCO.2005.05.2498 http://doi.org/10.1200/JCO.2005.05.2498 https://ascopubs.org/doi/10.1200/JCO.2005.05.2498 https://ascopubs.org/doi/10.1200/JCO.2005.05.2498

BLANK C U , ROZEMAN E A , FANCHI L F , et al . Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage Ⅲ melanoma [J ] . Nat Med , 2018 , 24 ( 11 ): 1655 - 1661 . DOI: 10.1038/s41591-018-0198-0 http://doi.org/10.1038/s41591-018-0198-0 https://doi.org/10.1038/s41591-018-0198-0 https://doi.org/10.1038/s41591-018-0198-0

ROZEMAN E A , MENZIES A M , VAN AKKOOI A C J , et al . Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage Ⅲ melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial [J ] . Lancet Oncol , 2019 , 20 ( 7 ): 948 - 960 . DOI: 10.1016/S1470-2045(19)30151-2 http://doi.org/10.1016/S1470-2045(19)30151-2 https://linkinghub.elsevier.com/retrieve/pii/S1470204519301512 https://linkinghub.elsevier.com/retrieve/pii/S1470204519301512

REIJERS I L M , MENZIES A M , VAN AKKOOI A C J , et al . Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage Ⅲ melanoma: the PRADO trial [J ] . Nat Med , 2022 , 28 ( 6 ): 1178 - 1188 . DOI: 10.1038/s41591-022-01851-x http://doi.org/10.1038/s41591-022-01851-x https://doi.org/10.1038/s41591-022-01851-x https://doi.org/10.1038/s41591-022-01851-x

AMARIA R N , REDDY S M , TAWBI H A , et al . Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma [J ] . Nat Med , 2018 , 24 ( 11 ): 1649 - 1654 . DOI: 10.1038/s41591-018-0197-1 http://doi.org/10.1038/s41591-018-0197-1

AMARIA R N , POSTOW M , BURTON E M , et al . Neoadjuvant relatlimab and nivolumab in resectable melanoma [J ] . Nature , 2022 , 611 ( 7934 ): 155 - 160 . DOI: 10.1038/s41586-022-05368-8 http://doi.org/10.1038/s41586-022-05368-8 https://doi.org/10.1038/s41586-022-05368-8 https://doi.org/10.1038/s41586-022-05368-8

WANG X , CUI C L , SI L , et al . A phase Ⅰb clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage Ⅲb to stage ⅣM 1a acral melanoma [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 9570 . DOI: 10.1200/JCO.2021.39.15_suppl.9570 http://doi.org/10.1200/JCO.2021.39.15_suppl.9570 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9570 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.9570

CUI C L , et al . 796P Neoadjuvant toripalimab plus axitinib in patients (pts) with resectable mucosal melanoma (MuM): updated findings of a single-arm, phase Ⅱ trial [J ] . Ann Oncol , 2022 , 33 : S908 .

AMARIA R N , PRIETO P A , TETZLAFF M T , et al . Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial [J ] . Lancet Oncol , 2018 , 19 ( 2 ): 181 - 193 . DOI: S1470-2045(18)30015-9 http://doi.org/S1470-2045(18)30015-9

LONG G V , SAW R P M , LO S , et al . Neoadjuvant dabrafenib combined with trametinib for resectable, stageⅢB-C, BRAF V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial [J ] . Lancet Oncol , 2019 , 20 ( 7 ): 961 - 971 . DOI: 10.1016/S1470-2045(19)30331-6 http://doi.org/10.1016/S1470-2045(19)30331-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204519303316 https://linkinghub.elsevier.com/retrieve/pii/S1470204519303316

AMARIA R N , et al . Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium [J ] . Lancet Oncol , 2019 , 20 ( 7 ): e378 -e389. DOI: 10.1016/S1470-2045(19)30332-8 http://doi.org/10.1016/S1470-2045(19)30332-8 https://linkinghub.elsevier.com/retrieve/pii/S1470204519303328 https://linkinghub.elsevier.com/retrieve/pii/S1470204519303328

MUELLER K L , THEORET M R , LEMERY S J , et al . Neoadjuvant therapy for melanoma: a US Food and Drug Administration-melanoma research alliance public workshop [J ] . Clin Cancer Res , 2021 , 27 ( 2 ): 394 - 401 . DOI: 10.1158/1078-0432.CCR-20-3285 http://doi.org/10.1158/1078-0432.CCR-20-3285

浏览量

2936

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

早期乳腺癌局部治疗与全身治疗的进展与展望

高危前列腺癌围手术期综合治疗专家共识（2023年版）

放射治疗在胃癌全程管理中的现状与挑战

乳腺癌新辅助治疗后的腋窝管理及前哨淋巴结诊治的优化

MRI预测乳腺癌淋巴结状态的研究进展及展望